C12N 2750/14051
Methods of production or purification of viral material
C12N2750/14051 (Methods of production or purification of viral material) appears on 14 US grants and 29 published applications in this corpus.
Search patents in C12N- Granted patents
- 14
- Published applications
- 29
- Assignees
- 21
- Inventors
- 71
- Latest grant
- 22 Apr 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 1 |
| 2009 | 0 | 2 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 2 | 1 |
| 2013 | 1 | 1 |
| 2014 | 0 | 2 |
| 2015 | 1 | 2 |
| 2016 | 1 | 1 |
| 2017 | 1 | 0 |
| 2018 | 0 | 1 |
| 2019 | 2 | 3 |
| 2020 | 1 | 2 |
| 2021 | 1 | 0 |
| 2022 | 0 | 1 |
| 2023 | 0 | 3 |
| 2024 | 1 | 3 |
| 2025 | 1 | 4 |
| 2026 | 0 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Truncated dysferlin for treatment of dysferlinopathy22 Apr 2025US 12,281,145 B2Texas Tech University System
- Scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapy23 Jan 2024US 11,878,056 B2The Children’s Hospital of Philadelphia
- Method for purifying viruses or virus-like particles using a crosslinked cellulose hydrate membrane26 Jan 2021US 10,900,024 B2Sartorius Stedim Biotech GmbH
- Bioreactor production of virus from adherent cells1 Dec 2020US 10,851,350 B1Genelux Corporation
- Scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapy25 Jun 2019US 10,328,145 B2The Children’s Hospital of Philadelphia
- Adeno-associated virus structural plasmid capable of improving adeno-assocaited virus titer26 Feb 2026US 2026/0055427 A1Zhenjiang Probio Biotech Co., Ltd.
- Methods and pharmaceutical compositions for the treatment and the prevention of alzheimers disease8 Jan 2026US 2026/0007706 A1Cornell University
- Virus-derived construct plasmid library and construction of same4 Sep 2025US 2025/0277236 A1Synplogen Co., Ltd.
- Engineered viral vectors with enhanced packaging capacity and methods of using the same29 May 2025US 2025/0171806 A1Massachusetts Institute of Technology
- Method for inhibiting zophobas morio black wasting disease24 Apr 2025US 2025/0127883 A1Rutgers, The State University of New Jersey
Most cited
By later US patents
- Cell line derived from Penaeus monodon and a method of growing virus using the same52US 6,143,547 AAcademia Sinica · 2000
- Scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapy19US 9,408,904 B2The Children’s Hospital of Philadelphia · 2016
- Method for growing crustacean virus in fish cells2US 5,236,840 AUniversity of Hawaii · 1993
- Bioreactor production of virus from adherent cells1US 10,851,350 B1Genelux Corporation · 2020
- Vaccines containing canine parvovirus genetic variants1US 8,227,583 B2The Board of Regents for Oklahoma State University · 2012